ProCE Banner Activity

Current and Future Therapeutic Strategies for Multiple Myeloma

In this Interactive Virtual Presentation, gain case-based insights in incorporating new findings and novel agents into the treatment paradigm for patients with multiple myeloma.

Released: June 23, 2020

Expiration: June 22, 2021

Share

Faculty

Peter Michael Voorhees

Peter Michael Voorhees, MD

Assistant Professor of Medicine
Department of Hematology/Oncology
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

Celgene

Janssen administered by Scientific Affairs

Oncopeptides

Faculty Disclosure

Primary Author

Peter Michael Voorhees, MD

Assistant Professor of Medicine
Department of Hematology/Oncology
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Peter M. Voorhees, MD, has no relevant conflicts of interest to report.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has reported that his spouse/partner has ownership interest (stock) in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.